NTRA
Natera, Inc. · Healthcare · Medical - Diagnostics & Research
Momentum inputs (comparable managers):
holder breadth -4.8% ·
share flow +1.9% ·
net new positions -5.0%
— formula
Concentrated accumulation — rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 162 | 0 | 104.13M | $28.25B | +5 | −4 |
| Q1 2026 | 164 | +3 | 98.65M | $19.54B | +6 | −4 |
| Q4 2025 | 160 | 0 | 102.31M | $23.44B | +1 | — |
| Q3 2025 | 23 | +1 | 81.70M | $13.15B | +1 | −1 |
| Q2 2025 | 20 | -1 | 57.32M | $9.68B | — | −1 |
| Q1 2025 | 18 | 0 | 31.15M | $4.40B | — | — |
| Q4 2024 | 18 | 0 | 26.97M | $4.27B | — | — |
| Q3 2024 | 17 | -1 | 21.42M | $2.72B | — | −1 |
| Q2 2024 | 18 | — | 16.29M | $1.76B | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 12.68M | — | $2.14B | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 2 | T. Rowe Price ✦ | 12.19M | +15.7% | $2.06B | 0.2% | ▲ Add | 5 | SEC ↗ ×2 |
| 3 | BlackRock ✦ (passive) | 10.96M | — | $1.85B | 0.0% | n/c | 1 | SEC ↗ ×22 |
| 4 | State Street Global Advisors ✦ (passive) | 3.32M | -1.6% | $560.46M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Duquesne Family Office ✦ | 3.09M | -9.3% | $521.21M | 13.3% | ▼ Trim | 5 | SEC ↗ |
| 6 | Wellington Management ✦ | 2.63M | -13.9% | $444.94M | 0.1% | ▼ Trim | 5 | SEC ↗ ×4 |
| 7 | Geode Capital Management ✦ (passive) | 2.55M | +7.0% | $430.64M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 8 | AQR Capital Management ✦ | 1.73M | +44.6% | $291.72M | 0.2% | ▲ Add | 5 | SEC ↗ ×6 |
| 9 | Norges Bank ✦ (passive) | 1.64M | +14.8% | $277.75M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | Fidelity (FMR) ✦ | 1.45M | — | $245.41M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Capital World Investors ✦ | 1.41M | +255.6% | $238.15M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 12 | ARK Investment Management ✦ | 936.39K | -0.7% | $158.19M | 1.2% | ▼ Trim | 5 | SEC ↗ |
| 13 | Citadel Advisors ✦ | 821.45K | -61.3% | $138.77M | 0.1% | ▼ Trim | 5 | SEC ↗ ×2 |
| 14 | Renaissance Technologies ✦ | 493.80K | +42.0% | $83.42M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 15 | Arrowstreet Capital ✦ | 483.24K | +29.3% | $81.64M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 16 | Two Sigma Investments ✦ | 252.44K | +230.2% | $42.65M | 0.1% | ▲ Add | 5 | SEC ↗ |
| 17 | Point72 Asset Management ✦ | 235.00K | -62.4% | $39.70M | 0.1% | ▼ Trim | 5 | SEC ↗ |
| 18 | Millennium Management ✦ | 176.51K | -31.0% | $29.82M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 19 | D. E. Shaw & Co. ✦ | 173.80K | -28.5% | $29.36M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 20 | Gotham Asset Management ✦ | 101.61K | -11.3% | $17.17M | 0.1% | ▼ Trim | 5 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Marshall Wace | $37.41M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 755 holders, 120.14M shares, $20.15B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 1.27K sh · $526,144
Director · 1.94K sh · $754,090
Director · 1.34K sh · $521,332
Director · 2.85K sh · $1.10M
Director · 2.30K sh · $889,271
Director · 390 sh · $150,263
Director · 110 sh · $42,946
Director · 2.32K sh · $904,069
Director · 1.29K sh · $502,598
Director · 2.73K sh · $1.06M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology